Description
Background:
Trastuzumab is a humanized monoclonal antibody which targets Her-2/neu receptor. It binds to an extracellular domain of this receptor and inhibits HER2 homodimerization, thereby preventing HER2-mediated signaling. It may also upregulate cell cycle inhibitors such as p21 and p27. Trastuzumab is also thought to facilitate antibody-dependent cellular cytotoxicity, leading to the death of cells that express HER2. It is approved for use in treating breast cancers and is being tested for other cancers that overexpress HER2/neu. At the time of its FDA approval in 1998, Trastuzumab was among the first available “targeted” chemotherapies. It is currently indicated for HER2 breast cancers and HER2 positive gastric cancer.
Intended Use:
For Estimation of Trastuzumab (HERCEPTIN) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Trastuzumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Trastuzumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Trastuzumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Trastuzumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!